Inovio Pharmaceuticals (INO) Retained Earnings (2016 - 2025)
Inovio Pharmaceuticals (INO) has disclosed Retained Earnings for 16 consecutive years, with -$637963.0 as the latest value for Q4 2025.
- Quarterly Retained Earnings rose 5.58% to -$637963.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$637963.0 through Dec 2025, up 5.58% year-over-year, with the annual reading at -$637963.0 for FY2025, 5.58% up from the prior year.
- Retained Earnings hit -$637963.0 in Q4 2025 for Inovio Pharmaceuticals, up from -$1.8 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$257932.0 in Q3 2021 to a low of -$1.8 billion in Q3 2025.
- Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.4 billion in 2022.
- Biggest five-year swings in Retained Earnings: skyrocketed 99.97% in 2021 and later tumbled 555621.91% in 2022.
- Year by year, Retained Earnings stood at -$282236.0 in 2021, then tumbled by 147.57% to -$698741.0 in 2022, then crashed by 232169.92% to -$1.6 billion in 2023, then surged by 99.96% to -$675667.0 in 2024, then grew by 5.58% to -$637963.0 in 2025.
- Business Quant data shows Retained Earnings for INO at -$637963.0 in Q4 2025, -$1.8 billion in Q3 2025, and -$1.8 billion in Q2 2025.